Product Description
NovoTTF-200T is a Tumor Treating Fields delivery system intended for use together with atezolizumab and bevacizumab for the treatment of patients with advanced liver cancer. (Sourced from: https://www.novocure.com/fda-grants-breakthrough-device-designation-to-the-novottf-200t-system-for-advanced-liver-cancer/)
Mechanisms of Action: Device
Novel Mechanism: No
Modality: Device
Route of Administration: Transdermal,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: NovoCure
Company Location: ST. HELIER Y9 JE2 4UF
Company CEO: Asaf Danziger
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, Bulgaria, Canada, China, Croatia, Czech Republic, France, Germany, Hong Kong, Hungary, Italy, Netherlands, Poland, Serbia, Spain, Switzerland, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Phase 2: Adenocarcinoma|Pancreatic Cancer|Pancreatic Ductal Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BTCRC GI21-500 | P2 |
Recruiting |
Pancreatic Cancer|Adenocarcinoma |
2027-08-01 |
|
| NCT05764954 | P1 |
Recruiting |
Adenocarcinoma |
2027-08-01 |
|
| EF-39 PANOVA-4 | P2 |
Recruiting |
Pancreatic Cancer|Adenocarcinoma|Pancreatic Ductal Carcinoma |
2026-08-01 |
23% |
| LUNAR | P3 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2023-09-01 |
31% |